SHANGHAI JUNSHI BIO YC1

Research SHANGHAI JUNSHI BIO YC1 (8SJ) on Bullrun: market cap EUR 1.86B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker8SJ
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 1.86B
• Financial periodFY2025
• RevenueEUR 2.50B
• Revenue growth28.2%
• Net income-EUR 840.91M
• Free cash flow-EUR 1.28B
• Gross margin79.1%

Valuation Snapshot

latest market cap is EUR 1.86B.

About SHANGHAI JUNSHI BIO YC1

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis;

Frequently asked questions

What is SHANGHAI JUNSHI BIO YC1's market cap?

SHANGHAI JUNSHI BIO YC1's market capitalization is EUR 1.86B.

What does SHANGHAI JUNSHI BIO YC1 do?

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.